Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
39.779
Neutral
STOCH(KDJ)(9,3,3)
28.688
Neutral
ATR(14)
0.070
Low Volatility
CCI(14)
-141.196
Sell
Williams %R
69.565
Sell
TRIX(12,20)
-0.489
Sell
StochRSI(14)
64.556
Buy
SNDL Inc
SNDL1.510USD
+0.060+4.14%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
388.67MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of SNDL Inc
Currency: USD Updated: 2026-02-06Key Insights
SNDL Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.60.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
SNDL Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
SNDL Inc Highlights
StrengthsRisks
SNDL Inc., through its wholly owned subsidiaries, is a vertically integrated cannabis company and a private-sector liquor and cannabis retailer in Canada. Its retail banners include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds and Spiritleaf. With products available in licensed cannabis retail locations nationally, its consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Gron, No Future and Bhang Chocolate. Its liquor retail segment includes the sales of wines, beers and spirits. Its cannabis retail segment includes the sales of cannabis products and accessories through corporate-owned and franchised cannabis retail operations. Its cannabis operations segment operates as a licensed producer that grows cannabis using indoor facilities and manufactures cannabis products, providing cannabis processing services. Its investments segment includes deployment of capital to investment opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.37% year-on-year.
Fairly Valued
The company’s latest PE is -5.98, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 59.69M shares, increasing 18.91% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 194.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.63.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.601
Target Price
+259.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of SNDL Inc is 8.13, ranking 84 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 173.17M, representing a year-over-year increase of 1.05%, while its net profit experienced a year-over-year increase of 32.46%.
Score
Financials
9.11
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
4.84
Operational Efficiency
10.00
Growth Potential
9.22
Shareholder Returns
7.47
SNDL Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of SNDL Inc is 8.85, ranking 4 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -5.98, which is -80.01% below the recent high of -1.20 and -71.75% above the recent low of -10.27.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 74/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of SNDL Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 5.60, with a high of 6.20 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.601
Target Price
+259.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
SNDL Inc
SNDL
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of SNDL Inc is 6.76, ranking 108 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.66 and the support level at 1.40, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.528
Sell
MA10
1.551
Sell
MA20
1.589
Sell
MA50
1.705
Sell
MA100
1.964
Sell
MA200
1.795
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of SNDL Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 23.19%, representing a quarter-over-quarter increase of 28.79%. The largest institutional shareholder is Invesco, holding a total of 194.30K shares, representing 0.08% of shares outstanding, with 67.83% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SNDL Inc is 3.82, ranking 98 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.74. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. SNDL Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.73
VaR
+6.10%
240-Day Maximum Drawdown
+48.49%
240-Day Volatility
+65.15%
Return
Best Daily Return
60 days
+24.86%
120 days
+24.86%
5 years
+27.82%
Worst Daily Return
60 days
-13.12%
120 days
-15.07%
5 years
-23.34%
Sharpe Ratio
60 days
-0.51
120 days
-0.57
5 years
-0.15
Risk Assessment
Maximum Drawdown
240 days
+48.49%
3 years
+54.34%
5 years
+90.62%
Return-to-Drawdown Ratio
240 days
-0.20
3 years
-0.02
5 years
-0.19
Skewness
240 days
+1.80
3 years
+1.38
5 years
+1.05
Volatility
Realised Volatility
240 days
+65.15%
5 years
+74.29%
Standardised True Range
240 days
+6.26%
5 years
+13.80%
Downside Risk-Adjusted Return
120 days
-94.08%
240 days
-94.08%
Maximum Daily Upside Volatility
60 days
+67.92%
Maximum Daily Downside Volatility
60 days
+56.05%
Liquidity
Average Turnover Rate
60 days
+1.21%
120 days
+0.90%
5 years
--
Turnover Deviation
20 days
+63.10%
60 days
+4.38%
120 days
-21.73%
Peer Comparison
Pharmaceuticals
SNDL Inc
SNDL
6.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
